Summary: In an exploratory analysis of two Phase 2 randomised trials, the oral non-peptide GLP-1 receptor agonist orforglipron was associated with significant placebo-adjusted reductions in cardiovascular risk biomarkers (blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP) in adults with type 2 diabetes (N=361, 26 weeks) and in adults with overweight or obesity without diabetes (N=234, 36 weeks). Improvements at 12 mg were of similar magnitude to those at higher doses. These are biomarker signals, not cardiovascular event outcomes.
PICO Summary
| Element | Detail |
|---|---|
| Population | Adults with available samples from two Phase 2 randomised trials: a type 2 diabetes cohort (N=361; mean age 59 years, 40% female, mean HbA1c 8.1%, mean BMI 35.3 kg/m2) and an overweight/obesity-without-diabetes cohort (N=234; mean age 54 years, 60% female, mean BMI 37.9 kg/m2). |
| Intervention | Once-daily oral orforglipron. T2D study: 3, 12, 24, 36, or 45 mg. Obesity study: 12, 24, 36, or 45 mg. Change from baseline assessed at 26 weeks (T2D) and 36 weeks (obesity). |
| Comparison | Placebo. The T2D trial also included an open-label active arm of once-weekly subcutaneous dulaglutide 1.5 mg, but the biomarker analysis was placebo-adjusted. |
| Outcome | Significant placebo-adjusted decreases from baseline in systolic/diastolic blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP were reported in both cohorts. The abstract reports direction and statistical significance only and does not provide effect sizes, 95% CIs, p-values, or ARR/NNT; no major adverse cardiovascular events were measured. Improvements with 12 mg were similar in magnitude to those with 24, 36, and 45 mg. |
Expert Commentary
This is best read as a hypothesis-generating signal, not proof of cardiovascular benefit. The work is an exploratory, secondary analysis of biomarkers drawn from two Phase 2 trials, so the findings are associational and surrogate. Placebo-adjusted reductions in blood pressure, atherogenic lipids, ApoB, ApoC3, and hsCRP are directionally encouraging and biologically coherent for a GLP-1 receptor agonist, and the apparent plateau at 12 mg is clinically interesting if it holds. The central limitation is that no clinical cardiovascular events were captured; favourable movement in surrogate markers has repeatedly failed to translate into event reduction, and only an adequately powered outcomes trial can settle that question. The analysis was conducted and funded by the manufacturer, with most authors employed by the sponsor, and the trials were short and modestly sized, all of which warrants cautious interpretation. The effect sizes are not implausibly large, which is reassuring. Can I use this with my patients? Not yet as a cardiovascular indication. For a patient with type 2 diabetes or obesity already prescribed orforglipron for glycaemia or weight, these biomarker shifts are a welcome bonus rather than a treatment rationale. The completed cardiovascular outcomes programme should be awaited before any heart-protection claim is made.
References
Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, et al. Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025;24(1):240. doi:10.1186/s12933-025-02781-x
